187.51
3.68 (2.00%)
| Penutupan Terdahulu | 183.83 |
| Buka | 184.02 |
| Jumlah Dagangan | 118,637 |
| Purata Dagangan (3B) | 220,910 |
| Modal Pasaran | 3,690,519,296 |
| Harga / Pendapatan (P/E TTM) | 82.97 |
| Harga / Pendapatan (P/E Ke hadapan) | 24.21 |
| Harga / Jualan (P/S) | 18.22 |
| Harga / Buku (P/B) | 4.24 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2026 |
| Margin Keuntungan | -73.07% |
| Margin Operasi (TTM) | -80.87% |
| EPS Cair (TTM) | -7.29 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 46.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.56% |
| Nisbah Semasa (MRQ) | 5.27 |
| Aliran Tunai Operasi (OCF TTM) | 52.87 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 63.35 M |
| Pulangan Atas Aset (ROA TTM) | -1.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Ligand Pharmaceuticals Incorpor | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | 0.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.60 |
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.35% |
| % Dimiliki oleh Institusi | 100.00% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 270.00 (Citigroup, 43.99%) | Beli |
| Median | 237.00 (26.39%) | |
| Rendah | 230.00 (Stifel, 22.66%) | Beli |
| Purata | 243.50 (29.86%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 184.39 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Feb 2026 | 239.00 (27.46%) | Beli | 183.65 |
| RBC Capital | 10 Dec 2025 | 235.00 (25.33%) | Beli | 184.03 |
| Stifel | 10 Dec 2025 | 230.00 (22.66%) | Beli | 184.03 |
| Citigroup | 09 Dec 2025 | 270.00 (43.99%) | Beli | 185.83 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| DAVIS TODD C | 183.83 | 183.83 | 27,549 | 5,064,333 |
| ESPINOZA OCTAVIO | 183.83 | 183.83 | 4,437 | 815,654 |
| REARDON ANDREW | 183.83 | 183.83 | 6,058 | 1,113,642 |
| Jumlah Keseluruhan Kuantiti Bersih | 38,044 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 6,993,629 | |||
| Purata Pembelian Keseluruhan ($) | 183.83 | |||
| Purata Jualan Keseluruhan ($) | 183.83 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| DAVIS TODD C | Pegawai | 15 Feb 2026 | Dibuang (-) | 9,099 | 183.83 | 1,672,669 |
| ESPINOZA OCTAVIO | Pegawai | 15 Feb 2026 | Dibuang (-) | 3,519 | 183.83 | 646,898 |
| REARDON ANDREW | Pegawai | 15 Feb 2026 | Dibuang (-) | 2,386 | 183.83 | 438,618 |
| DAVIS TODD C | Pegawai | 14 Feb 2026 | Diperolehi (+) | 60,426 | 183.83 | 11,108,112 |
| DAVIS TODD C | Pegawai | 14 Feb 2026 | Dibuang (-) | 23,778 | 183.83 | 4,371,110 |
| ESPINOZA OCTAVIO | Pegawai | 14 Feb 2026 | Diperolehi (+) | 16,200 | 183.83 | 2,978,046 |
| ESPINOZA OCTAVIO | Pegawai | 14 Feb 2026 | Dibuang (-) | 8,244 | 183.83 | 1,515,495 |
| REARDON ANDREW | Pegawai | 14 Feb 2026 | Diperolehi (+) | 15,738 | 183.83 | 2,893,117 |
| REARDON ANDREW | Pegawai | 14 Feb 2026 | Dibuang (-) | 7,294 | 183.83 | 1,340,856 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
| 09 Dec 2025 | Pengumuman | Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |